Antares Pharma to Present at the Ladenburg Thalmann 2015 Healthcare Conference
September 24 2015 - 11:00AM
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Eamonn P.
Hobbs, President and Chief Executive Officer, will present at the
Ladenburg Thalmann 2015 Healthcare Conference on Tuesday, September
29, 2015 at 3:30 p.m. Eastern Time.
A live webcast of the presentation will be
available via the webcast tab under the Investor Information page
of the Antares website, www.antarespharma.com. A replay of the
webcast will also be archived on Antares’ website for 90 days
following the presentation.
About Antares Pharma
Antares Pharma focuses on self-administered
parenteral pharmaceutical products. The Company’s product, OTREXUP™
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. Antares
Pharma is also developing QuickShot® Testosterone for testosterone
replacement therapy, and VIBEX® Sumatriptan for the acute treatment
of migraines. The Company's technology platforms include
VIBEX® disposable auto injectors, disposable multi-use pen
injectors and reusable needle-free injectors. Antares Pharma has a
multi-product deal with Teva Pharmaceutical Industries, Ltd. that
includes VIBEX® epinephrine, exenatide multi-dose pen, and another
undisclosed multi-dose pen. Our reusable needle-free injector
for use with human growth hormone (hGH) is sold worldwide by
Ferring B.V.
Contact:
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024